Videos

Dr Matthew Lunning describes the available third- and subsequent-line treatments for patients with relapsed/refractory DLBCL (R/R DLBCL) who aren’t eligible for transplant.

An expert explains the options for patients with DLBCL who develop chemorefractory disease in second-line treatment.

Matthew Lunning, DO, FACP, presents the case of a 64-year-old man with diffuse large B-cell lymphoma (DLBCL) and shares his initial impressions.

Adam Weiner, MD, discusses the importance of molecular testing for prostate cancer and what the current targeted therapy landscape looks like for this disease.

Dr Tanya Dorff presents the case of a 72-year-old man with metastatic hormone-sensitive prostate cancer.

A review of data from the ALSYMPCA clinical trial on the use of radium-223 for prostate cancer treatment.

An expert in breast cancer considers the role of intravenous and fixed-dose subcutaneous formulations of trastuzumab/pertuzumab as studied in the FeDeriCa and PHranceSCa clinical trials.

Chau T. Dang, MD, considers the case of a patient with early-stage HER2+ BC and discusses risk assessment and factors to consider when selecting between neoadjuvant and adjuvant treatment.

Key opinion leaders review the case of a 72-year-old man with metastatic CSPC and consider optimal treatment approaches in this setting.

Comprehensive insight on darolutamide therapy in nonmetastatic CRPC, supported by clinical data from the ARAMIS trial.

Yonina R. Murciano-Goroff, MD, MSc, DPhil, addresses remaining clinical questions for the treatment of MET fusion positive patients with non–small cell lung cancer.

Gabriela Hobbs, MD, discusses the unmet needs that have yet to be filled in the post-myeloproliferative neoplasm acute leukemia space.

Siddhartha Mukherjee, MD, explains the current golden standard for frontline treatment of patients with acute myeloid leukemia.

Lori J. Wirth, MD, discusses sequencing therapies for patients with NTRK fusion–positive advanced thyroid cancer.

Comprehensive discussion on the PFS subgroup data from REFLECT, which compared frontline lenvatinib and sorafenib therapy in metastatic HCC.

Shared insight on clinical trial data in metastatic hepatocellular carcinoma supporting frontline use of sorafenib and lenvatinib, respectively.

Ronald L. Paquette, MD, discusses how age impacts the use of bone marrow and stem cell transplants in patients with myelodysplastic syndrome.

Ryan Sugarman, MD, discusses the key takeaways from the CheckMate-649 trial of patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma receiving nivolumab combined with chemotherapy compared with chemotherapy alone in the first-line.

Dr Grzegorz S. Nowakowski muses on the unmet needs of patients with DLBCL and the emerging treatment options he looks forward to.

An expert describes factors for consideration when choosing a second-line treatment for relapsed DLBCL.

Grzegorz S. Nowakowski, MD, reviews the approved further-line treatment options for relapsed DLBCL.

An explanation of the design, efficacy, and adverse events of L-MIND, a trial investigating a combination treatment for R/R DLBCL.

Dr Grzegorz S. Nowakowski reviews the currently available second-line treatment options for transplant-ineligible R/R DLBCL.

A discussion on the clinical factors that put patients at risk of having relapsed DLBCL.

Bruce Feinberg, DO, discusses a survey researching chimeric antigen receptor T-cell therapy’s growing usage by community oncologists for diffuse large B-cell lymphoma.

Manali Kamdar, MD, discusses data from the 2 clinical trials that supported the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma.

Matthew S. McKinney, MD, discusses the tolerability observed in the LOTIS-2 trial of loncastuximab tesirine of patients with relapsed/refractory diffuse large B-cell lymphoma.

Shared insight on how expert oncologists select therapy for patients with nonmetastatic castration-resistant prostate cancer.

Expert perspectives on optimal patient follow-up, with particular regard for PSMA imaging, in nonmetastatic castration-resistant prostate cancer.

Neil Vasan, MD, PhD, discusses how past studies have supported de-escalated approaches and other improvements to treatment for patients with HER2-positive breast cancer.